source
- Vaccine biotech Evaxion halts infectious disease, autoimmune work to focus on oncologyEvaxion is refocusing its R&D efforts to solely focus on developing and advancing its cancer vaccines.Fierce Biotech · 6h ago↗ source
- GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent dealGSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…